350 related articles for article (PubMed ID: 29446164)
1. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
[TBL] [Abstract][Full Text] [Related]
2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
Nishie W
Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
[TBL] [Abstract][Full Text] [Related]
4. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
[No Abstract] [Full Text] [Related]
5. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
6. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
8. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes.
Guliani A; Bishnoi A; Aggarwal D; Parsad D
Postgrad Med J; 2018 Nov; 94(1117):662-663. PubMed ID: 30317183
[No Abstract] [Full Text] [Related]
9. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
[TBL] [Abstract][Full Text] [Related]
10. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
Front Immunol; 2018; 9():542. PubMed ID: 29706950
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
Kitao R; Fukumoto T; Hashimoto T; Izumi K; Jimbo H; Takemori C; Nishigori C
J Dermatol Sci; 2021 Sep; 103(3):190-192. PubMed ID: 34489165
[No Abstract] [Full Text] [Related]
12. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
[No Abstract] [Full Text] [Related]
13. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
[No Abstract] [Full Text] [Related]
14. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
[TBL] [Abstract][Full Text] [Related]
15. Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement.
Kage Y; Yamaguchi Y; Uchida T; Izumi K; Nishie W; Shimizu H; Ishii N; Hashimoto T; Aihara M
J Dermatol; 2018 Jul; 45(7):e205-e206. PubMed ID: 29380425
[No Abstract] [Full Text] [Related]
16. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid.
Izumi K; Nishie W; Mai Y; Wada M; Natsuga K; Ujiie H; Iwata H; Yamagami J; Shimizu H
J Invest Dermatol; 2016 Nov; 136(11):2201-2210. PubMed ID: 27424319
[TBL] [Abstract][Full Text] [Related]
18. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
García-Díez I; España A; Iranzo P
Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
[No Abstract] [Full Text] [Related]
19. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.
Tuusa J; Kokkonen N; Mattila A; Huilaja L; Varpuluoma O; Rannikko S; Glumoff V; Miettunen J; Tasanen K
J Invest Dermatol; 2023 Jan; 143(1):78-86.e12. PubMed ID: 35921900
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.
Gambichler T; Espey B; Doerler M; Stranzenbach R
Actas Dermosifiliogr; 2022 Oct; 113(9):914-915. PubMed ID: 35636509
[No Abstract] [Full Text] [Related]
[Next] [New Search]
